2021
The Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemotherapy: A Double-Blinded Study
Post G, Lustgarten J. The Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemotherapy: A Double-Blinded Study. Topics In Companion Animal Medicine 2021, 46: 100616. PMID: 34864255, DOI: 10.1016/j.tcam.2021.100616.Peer-Reviewed Original ResearchConceptsOligo-FucoidanComplete blood countLife metricsLife scoresDouble-blinded studyMinimal adverse side effectsCase-control studyPlacebo control groupAdverse side effectsSignificant differencesQuality of lifeDiagnosis of cancerSerum biochemical parametersSerum biochemistry profilePlacebo groupUndergoing ChemotherapyProspective studyPhysical examinationBlood countCancer CenterFucoidan groupBlinded cliniciansLife QuestionnaireVeterinary patientsSide effects
2017
Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia
Berger E, Johannes C, Post G, Rothchild G, Shiu K, Wetzel S, Fox L. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia. Journal Of Feline Medicine And Surgery 2017, 20: 95-102. PMID: 29172873, PMCID: PMC11129263, DOI: 10.1177/1098612x17695898.Peer-Reviewed Original ResearchConceptsMast cell neoplasiaCell neoplasiaAdverse eventsClinical benefitUse of toceranibDuration of therapyPossible clinical benefitFurther prospective studiesMajority of catsVeterinary Internal MedicineHematologic eventsToceranib treatmentGastrointestinal involvementMedian doseMedian durationDose adjustmentTreatment breaksProspective studyConcurrent treatmentAmerican CollegeRetrospective evaluationAnatomic classificationFeline patientsGastrointestinal casesToceranib
2014
Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses
Roberts N, Zhang L, Janku F, Collins A, Bai R, Staedtke V, Rusk A, Tung D, Miller M, Roix J, Khanna K, Murthy R, Benjamin R, Helgason T, Szvalb A, Bird J, Roy-Chowdhuri S, Zhang H, Qiao Y, Karim B, McDaniel J, Elpiner A, Sahora A, Lachowicz J, Phillips B, Turner A, Klein M, Post G, Diaz L, Riggins G, Papadopoulos N, Kinzler K, Vogelstein B, Bettegowda C, Huso D, Varterasian M, Saha S, Zhou S. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Science Translational Medicine 2014, 6: 249ra111. PMID: 25122639, PMCID: PMC4399712, DOI: 10.1126/scitranslmed.3008982.Peer-Reviewed Original ResearchConceptsC. novyi-NT sporesIntratumoral injectionHuman patientsCanine tumorsFurther clinical trialsOrthotopic brain tumor modelC. novyi-NTBrain tumor modelClostridium novyi-NT sporesSpontaneous solid tumorsCommon toxicitiesObjective responsePartial responseAdvanced leiomyosarcomaAntitumor responseClinical trialsHeterogeneous genetic backgroundHuman trialsSolid tumorsBacterial infectionsNeoplastic tissueTumor modelTumorsTherapeutic agentsPatients
2005
A Phase I Clinical Trial Evaluating Imatinib Mesylate (Gleevec) in Tumor‐Bearing Cats
Lachowicz J, Post G, Brodsky E. A Phase I Clinical Trial Evaluating Imatinib Mesylate (Gleevec) in Tumor‐Bearing Cats. Journal Of Veterinary Internal Medicine 2005, 19: 860-864. PMID: 16355681, DOI: 10.1111/j.1939-1676.2005.tb02778.x.Peer-Reviewed Original ResearchConceptsPhase I clinical trialPO q24hImatinib mesylateClinical trialsSerum biochemistryMinimal gastrointestinal toxicityTumor-bearing catsTumor‐Bearing CatsDiagnosis of fibrosarcomaSquamous cell carcinomaTyrosine kinase inhibitorsMast cell tumorsSigns of toxicityAbdominal ultrasonographyConcurrent chemotherapyGastrointestinal toxicityDose escalationCell carcinomaCell tumorsThoracic radiographsQ24hRadiation therapyMost catsFurther evaluationKinase inhibitors
2003
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clinical Cancer Research 2003, 9: 2755-68. PMID: 12855656.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsDog DiseasesDogsDose-Response Relationship, DrugEnzyme InhibitorsFemaleIndolesInhibitory Concentration 50MaleModels, ChemicalMutationNeoplasmsProto-Oncogene Proteins c-kitPyrrolesReceptor Protein-Tyrosine KinasesReceptors, Vascular Endothelial Growth FactorTime FactorsTomography, X-Ray ComputedConceptsReceptor tyrosine kinase inhibitorsTyrosine kinase inhibitorsGrowth factor receptorKinase inhibitorsSpontaneous malignanciesSpontaneous tumorsSmall molecule receptor tyrosine kinase inhibitorPhase I dose-escalating studyDose-escalating studyMeasurable objective responseSimilarities of canineVascular endothelial growth factor receptorStandard treatment regimensFactor receptorPhase I trialEndothelial growth factor receptorOverall response rateSoft tissue sarcomasPlatelet-derived growth factor receptorMast cell tumorsVariety of cancersStable diseaseObjective responseOral therapyProgressive disease